Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini Oral session: Haematological malignancies

625MO - Combination of mitoxantrone hydrochloride liposome with pegaspargase in patients with extranodal NK/T-cell lymphoma: A phase I/II clinical trial

Date

12 Sep 2022

Session

Mini Oral session: Haematological malignancies

Topics

Tumour Site

Haematological Malignancies

Presenters

Yunhong Huang

Citation

Annals of Oncology (2022) 33 (suppl_7): S283-S294. 10.1016/annonc/annonc1055

Authors

Y. Huang1, T. Wu1, Y. Hu1, Y. Li2, J. Ma3, Y. Guo4, H. Zhou5, R. Yang6, Y. Gong7, Q.Y. Zhang8, L.E. Lin9, R. Zhou10, Y. Liu10, Z. Pan11, J. Xue12, D. Wang12

Author affiliations

  • 1 Department Of Oncology, Affiliated Hospital of Guizhou Medical University, 550000 - Guiyang/CN
  • 2 Department Of Hematology, Henan Cancer Hospital/Affiliated Cancer Hospital of Zhengzhou University, 450008 - Zhengzhou/CN
  • 3 Department Of Oncology, The First Affiliated Hospital of Guangxi Medical University, 530021 - Nanning/CN
  • 4 Department Of Oncology, The First Affiliated Hospital of Henan University of Science and Technology, 471002 - Luoyang/CN
  • 5 Department Of Lymphoma And Hematology, Hunan Cancer Hospital, 410013 - Changsha/CN
  • 6 The Second Department Of Medical Oncology, Yunnan Cancer Hospital & The Third Affiliated Hospital of Kunming Medical University & Yunnan Cancer Center, 650118 - Kunming/CN
  • 7 Department Of Phase I Clinical Trial Ward, Chongqing University Cancer Hospital, Chongqing/CN
  • 8 Department Of Medical Oncology, 3rd Affiliated Hospital of Harbin Medical University, 150081 - Harbin/CN
  • 9 Department Of Hematology, Hainan General Hospital, 570311 - Haikou/CN
  • 10 Clinical Development Division, CSPC Pharmaceutical Group Ltd., 050035 - Shijiazhuang/CN
  • 11 Biometrics, CSPC Pharmaceutical Group Ltd., 050035 - Shijiazhuang/CN
  • 12 Cancer Center, CSPC Zhongqi Pharmaceutical Technology Co., Ltd, Shijiazhuang/CN
More

Resources

Login to access the resources on OncologyPRO.

Abstract 625MO

Background

Extranodal NK/T-cell lymphoma (ENKTCL) remains a high unmet clinical need for improving outcome. This trial aimed to explore the safety, pharmacokinetics (PK) and efficacy of mitoxantrone hydrochloride liposome (PLM60) plus pegaspargase in patients (pts) with ENKTCL.

Methods

Adult pts with histologically confirmed treatment-naïve or relapsed/refractory ENKTCL were recruited. Phase I was 3+3 dose-escalation design with four dose levels of PLM60 (12, 16, 20 and 24 mg/m2) plus pegaspargase 2000 IU/m2 administered on day 1 of every cycle (21 days) for 4-6 cycles. Phase II was dose expansion at the recommended phase 2 dose (RP2D) in pts with treatment-naïve ENKTCL. The primary endpoints were safety and PK. The secondary endpoint was efficacy including complete response (CR) rate, objective response rate (ORR) as per Lugano 2014.

Results

At the cut-off data of February 15, 2022, 31 eligible pts were enrolled (phase I, n = 21 and phase II, n = 10). Phase I included 9 relapsed/refractory pts and 12 treatment-naïve pts. Two dose-limiting toxicities (grade-4 neutropenia in 20 mg/m2; grade-3 abdominal pain in 24 mg/m2) occurred. RP2D was PLM60 24 mg/m2 plus pegaspargase 2000 IU/m2. Treatment-related adverse events (TRAEs) of any grade occurred in all 31 pts, in which 27 (87.1%) were ≥ grade 3. The most common ≥ grade 3 TRAEs was neutropenia (77.4%), leucopenia (74.2%), anemia (54.8%), thrombocytopenia (45.2%), hypertriglyceridemia (22.6%), infectious pneumonia (16.1%), lymphocytopenia (16.1%), decreased fibrinogen level (16.1%), hypoglycemia (12.9%) and elevated bilirubin (12.9%). 31 pts were evaluable for response. CR rate and ORR were 61.3% (19/31, 95% CI 42.2%-78.2%) and 87.1% (27/31, 95% CI 70.2%-96.4%), respectively. Median PFS was not reached. Among 22 treatment-naïve pts (13 males) with a median age of 40.5 (range, 23-70), 9 pts (40.9%) had the presence of B symptoms and 6 pts (27.3%) were at the stage III or IV (Lugano classification). The CR rate and ORR of this cohort was 68.2% (15/22, 95% CI 45.1%-86.1%) and 90.9% (20/22, 95% CI 70.8%-98.9%).

Conclusions

PLM60 plus pegaspargase had an encouraging efficacy especially in treatment-naïve ENKTCL pts with manageable safety profiles.

Clinical trial identification

NCT04509466.

Editorial acknowledgement

Legal entity responsible for the study

CSPC Zhongqi Pharmaceutical Technology Co., Ltd.

Funding

This trial is funded by National key R&D Program of China (2017YFA0205604), and supported by CSPC Zhongqi Pharmaceutical Technology Co., Ltd.

Disclosure

R. Zhou: Financial Interests, Personal, Full or part-time Employment: CSPC. Y. Liu: Financial Interests, Personal, Full or part-time Employment: CSPC. Z. Pan: Financial Interests, Personal, Full or part-time Employment: CSPC. J. Xue: Financial Interests, Personal, Full or part-time Employment: CSPC. D. Wang: Financial Interests, Personal, Full or part-time Employment: CSPC. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.